Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Welsh regulator backs limited access to leukaemia drug

  • Comment
NHS patients in Wales should have access to a new treatment for chronic myeloid leukaemia (CML), according to the All Wales Medicines Strategy Group.

Dasatinib (Sprycel) has been recommended for the treatment of adults with chronic or accelerated phase CML, where there is resistance or intolerance to prior therapy including imatinib mesylate.

The drug is an oral tyrosine kinase inhibitor that blocks leukaemia cell growth, enabling adults with certain types of the CML to benefit from disease control over a sustained period of time.
  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs